P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 678-685

  Hsieh, Ya Ju ^a   Hwu, Luen ^b   Chen, Yi Chieh ^b,c   Ke, Chien Chih ^b   Chen, Fu Du ^d   Wang, Hsin Ell ^c   Lin, Kang Ping ^e   Yeh, Hsin Hsien ^b,c   Chang, Chi Wei ^b,f   Liu, Ren Shyan ^b,c,f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b National Comprehensive Mouse Phenotyping and Drug Testing Center   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHINESE CULTURE UNIVERSITY   (Taiwan)

^e CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Histone deacetylase inhibitor; HSV1 tk; P21; PET

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; FIREFLY LUCIFERASE; GANCICLOVIR; PROTEIN P53; THYMIDINE KINASE; TRICHOSTATIN A; VORINOSTAT;

ARTICLE; CANCER GENE THERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 1 GENE; DRUG EFFICACY; DSREDM GENE; ENZYME ACTIVITY; FEMALE; FIREFLY LUCIFERASE GENE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; THYMIDINE KINASE GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

18F-FHBG; HISTONE DEACETYLASE INHIBITOR; HSV1-TK; P21; PET;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; FEMALE; GENE FUSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; INDICATORS AND REAGENTS; LUCIFERASES; LUMINESCENCE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING; NEOPLASMS; PLASMIDS; POSITRON-EMISSION TOMOGRAPHY; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84901315813     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126573     Document Type: Article

References (41)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-692.
2. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84-100.
3. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol. 2005;17:55-60.
4. Buchwald M, Kramer OH, Heinzel T. HDACi: targets beyond chromatin. Cancer Lett. 2009;280:160-167.
5. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834-840.
6. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420-5432.
7. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280:168-176.
8. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552.
9. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540-545.
10. Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004;10:6962-6968.
11. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107-116.
12. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-784.
13. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009;280:125-133.
14. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009;280: 201-210.
15. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60:5165-5170.
16. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res. 2009;15:3918-3926.
17. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010;107:14639-14644.
18. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011;2011:514261.
19. Shabason JE, Tofilon PJ, Camphausen K. HDAC inhibitors in cancer care. Oncology. 2010;24:180-185.
20. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003;2:151-163.
21. Chiba T, Yokosuka O, Arai M, et al. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol. 2004;41:436-445.
22. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014-10019.
23. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol. 2002;64:1079-1090.
24. Hwu L, Lin C-F, Hwang A-L, et al. Stably quad-fused reporter gene expressed homogenous cancer cell xenograft for in vivo optical and microPET imaging [abstract]. J Nucl Med. 2008;49(suppl 1):167P.
25. Chang CW, Lin M, Wu SY, et al. A high yield robotic synthesis of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) and 9-[3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine([18F] FHPG) for gene expression imaging. Appl Radiat Isot. 2007;65:57-63.
26. Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997;272:22199-22206.
27. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun. 1997;241:142-150.
28. Ponzio G, Loubat A, Rochet N, et al. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction. Oncogene. 1998;17:1159-1166.
29. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer. 1999;80:1252-1258.
30. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 2007;39:1367-1374.
31. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400-414.
32. Roninson IB. Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179:1-14.
33. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-5468.
34. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007;16:659-678.
35. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene. 2000;19:5712-5719.
36. Ohtani N, Imamura Y, Yamakoshi K, et al. Visualizing the dynamics of p21Waf1/Cip1 cyclin-dependent kinase inhibitor expression in living animals. Proc Natl Acad Sci USA. 2007;104:15034-15039.
37. Chen Y-C, Hwu L, Lin K-H, Wang H-E, Liu R-S. Histone deacetylase inhibitor inducible gene expression for drugs screening and suicide gene therapy [abstract]. J Nucl Med. 2010; 51(suppl 2):200P.
38. Wong JC, Guo L, Peng Z, et al. Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy. Bioorg Med Chem Lett. 2011;21:110-116.
39. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61:3022-3026.
40. Wang WD, Chen ZT, Li R, Li DZ, Duan YZ, Cao ZH. Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements. Cancer Sci. 2005;96:918-924.
41. Gingrich JR, Roder J. Inducible gene expression in the nervous system of transgenic mice. Annu Rev Neurosci. 1998;21:377-405.